Histamine and spontaneous motor activity: Biphasic changes, receptors involved and participation of the striatal dopamine system

Life Sciences

Volumn 62, Issue 20, 1998, Pages 1875-1888

  Chiavegatto, Silvana ^a   Nasello, Antonia Gladys ^b   Bernardi, Maria Martha ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Department of Pharmacology Biomedical Sciences Institute University of Sao Paulo ^*

Author keywords

Dopamine; H3 receptor; Hetcroreceptor; Histamine; Motor activity; Striatal dopamine system

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; HISTAMINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR AGONIST; HISTAMINE H3 RECEPTOR ANTAGONIST; HOMOVANILLIC ACID; MEPYRAMINE; N METHYLHISTAMINE; NEUROTRANSMITTER; RANITIDINE; SEROTONIN; THIOPERAMIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; DOSE RESPONSE; HYPERACTIVITY; HYPOTHALAMUS; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; LOCOMOTION; MALE; MOTOR ACTIVITY; NONHUMAN; OPEN FIELD BEHAVIOR; RAT; REARING;

EID: 18744433712     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(98)00154-4     Document Type: Article

References (48)

1. 1. K. ONODERA, A. YAMATODANI, T. WATANABE and H. WADA, Progr. Neurobiol. 42 685-702 (1994).
2. 2. J.-C. SCHWARTZ, J.-M. ARRANG, M. GARBARG, H. POLLARD and M. RUAT, Physiol. Rev. 71 1-51 (1991).
3. 3. P.W. KALIVAS, J. Pharmacol. Exp. Ther. 222 37-42 (1982).
4. 4. G. NISTICO, D. ROTIROTI, A. DESARRO, F. NACCARI and J.D. STEPHENSON, Res. Commun. Chem. Pathol. Pharmacol. 27 431-450 (1980).
5. 5. L. TUOMISTO and L. ERIKSSON, Agents Actions 10 165-166 (1980).
6. 6. J.P. HANIG and J. SEIFTER, Arch. Int. Pharmacodyn. Ther. 202 38-47 (1973).
7. 7. C.R. CALCUTT and J. REYNOLDS, Neurosci. Lett. 3 82-83 (1976).
8. 8. K. ONODERA and Y. OGURA, Advances in Histamine Research, B. Uvnas and K. Tasaka (Eds), 127-136, Pergamon Press, Oxford (1981).
9. 9. E.O. ALVAREZ and A.M. BANZAN, Physiol. Behav. 34 661-664 (1985).
10. 10. E.O. ALVAREZ and A.M. BANZAN, Physiol. Behav. 37 39-45 (1986).
11. 11. E.O. ALVAREZ and F.A. GUERRA, Physiol. Behav. 28 1035-1040 (1982).
12. 12. J.M. ARRANG, M. GARBARG and J.C. SCHWARTZ, Nature 302 832-837 (1983).
13. 13. J.M. ARRANG, M. GARBARG and J.C. SCHWARTZ, Neuroscience 15 553-562 (1985).
14. 14. J.M. ARRANG, M. GARBARG and J.C. SCHWARTZ, Neuroscience 23 149-157 (1987).
15. 15. E. SCHLICKER, B. MALINOWSKA, M. KATHMANN and M. GOTHERT, Fundam. Clin. Pharmacol. 8 128-137 (1994).
16. 16. L.J. BRISTOW and G.W. BENNETT, Br. J. Pharmacol. 94 319P (1988).
17. 17. L.J. BRISTOW and G.W. BENNETT, Br. J. Pharmacol. 95 1292 (1988).
18. 18. N. SAKAI, K. ONODERA, K. MAEYAMA, K. YANAI and T. WATANABE, Life Sci. 48 2397-2404 (1991).
19. 19. M. IMAIZUMI and K. ONODERA, Life Sci. 53 1675-1683 (1993).
20. 20. L.J. PELLEGRINO, A.S. PELLEGRINO and A.J. CUSHMAN, A Stereotaxic Atlas of the Rat Brain, Plenum Press, New York (1979).
21. 21. A.G. NASELLO and O.A. RAMIREZ, Psychopharmacology 58 171-173 (1978).
22. 22. D.B. DUNCAN, Biometrics 11 1-42 (1955).
23. 23. C.W. DUNNETT, J. Am. Stat. Assoc. 50 1096-1121 (1955).
24. 24. X.A. ALVAREZ, A. FRANCO, L. FERNÁNDEZ-NOVOA and R. CACABELOS, Agents Actions 43 21-23 (1994).
25. 25. E.O. ALVAREZ and A.M. BANZAN, Behav. Brain Res. 48 127-133 (1992).
26. 26. A.E. FLECKENSTEIN, K.J. LOOKINGLAND and K.E. MOORE, Naunyn-Schmiedeberg's Arch. Pharmacol. 347 50-54 (1993).
27. 27. M. RUAT, E. TRAIFFORT, M.L. BOUTHENET, J.C. SCHWARTZ, J. HIRSCHFELD, A. BUSCHAUER and W. SCHUNACK, Proc. Natl. Acad. Sci. USA 87 1658-1662 (1990).
28. 28. T. SUZUKI, K. TAKAMORI, M. MISAWA and K. ONODERA, Brain Res. 675 195-202 (1995).
29. 29. J.M. ARRANG, B. DEVAUX, J.P. CHODKIEWICZ and J.C. SCHWARTZ, J. Neurochem. 51 105-108 (1988).
30. 30. J.M. ARRANG, M. GARBARG, J.C. LANCELOT, J.M. LECOMTE, H. POLLARD, M. ROBBA, W. SCHUNACK and J.C. SCHWARTZ, Nature 327 117-123 (1987).
31. 31. R. OISHI, Y. ITOH, M. NISHIBORI and K. SAEKI, J. Neurochem. 52 1388-1392 (1989).
32. 32. J.-S. LIN, K. SAKAI, G. VANNI-MERCIER, J.-M. ARRANG, M. GARBARG, J.-C. SCHWARTZ and M. JOUVET, Brain Res. 523 325-330 (1990).
33. 33. J. CLAPHAM and G.J. KILPATRICK, Eur. J. Pharmacol. 259 107-114 (1994).
34. 34. A.G. NASELLO, C. MACHADO, J.F. BASTOS and L.F. FELICIO, Physiol. Behav. 63 (2) in press (1998).
35. 35. R.J. BENINGER, Brain Res. Rev. 6 173-196 (1983).
36. 36. L. CÔTÉ and M.D. CRUTCHER, Principles of Neural Science, E.R. Kandel, J.H. Schwartz and T.M. Jessell (Eds), 647-659, Elsevier, New York (1991).
37. 37. J. ARNT, Dopamine Receptors, 1. Creese and C.M. Fraser (Eds), 199-231, Alan R. Liss, New York (1987).
38. 38. J.F. MARSHALL, J.S. RICHARDSON and P. TEITELBAUM, J. Comp. Physiol. Psychol. 87 808-830 (1974).
39. 39. J.Z. NOWAK and A. PILC, Eur. J. Pharmacol. 46 171-175 (1977).
40. 40. N. SUBRAMANIAN and A.H. MULDER, Eur. J. Pharmacol. 43 143-152 (1977).
41. 41. J.Z. NOWAK, Pol. J. Pharmacol. Pharm. 37 359-382 (1985).
42. 42. P. CUMMING, C. SHAW and S.R. VINCENT, Synapse 8 144-151 (1991).
43. 43. X. LIGNEAU, M. GARBARG, M.L. VIZUETE, J. DIAZ, K. PURAND, H. STARK, W. SCHUNACK and J.-C. SCHWARTZ, J. Pharmacol. Exp. Ther. 271 452-459 (1994).
44. 44. R.E. WEST, A. ZWEIG, R.T. GRANZOW, M.I. SIEGEL and R.W. EGAN, J. Neurochem. 55 1612-1616 (1990).
45. 45. E. SCHLICKER, K. FINK, M. DETZNER and M. GOTHERT, J. Neural Transm. 93 1-10 (1993).
46. 46. C. ITO, K. ONODERA, T. WATANABE and M. SATO, Psychopharmacology 130 362-367 (1997).
47. 47. A.E. FLECKENSTEIN, K.J. LOOKINGLAND and K.E. MOORE, Eur. J. Pharmacol. 254 35-42 (1994).
48. 48. A. PILC and J.Z. NOWAK, Eur. J. Pharmacol. 55 269-272 (1979).